Citi initiated coverage of Spyre Therapeutics (SYRE) with a Buy rating and $64 price target The firm says the company is developing “best-in-class” antibodies for autoimmune conditions. Citi sees meaningful upside potential in the company’s rheumatic disease program. It sees an inflection for the shares with data readouts in 2026 and 2027.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Buy Rating for Spyre Therapeutics Driven by Strong Stock Performance and Promising Clinical Developments
- Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 12/1/2025, According to Top Analysts
- Spyre Therapeutics upgraded to Buy from Hold at JonesResearch
- Spyre Therapeutics: Promising Innovations and Strong Financials Justify Buy Rating